Oragenics (NYSE:OGEN) Now Covered by StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Thursday. The firm issued a sell rating on the stock.

Oragenics Price Performance

Shares of NYSE:OGEN opened at $0.32 on Thursday. The business’s 50 day simple moving average is $0.34 and its 200 day simple moving average is $0.95. Oragenics has a 1 year low of $0.25 and a 1 year high of $7.74. The company has a market capitalization of $3.88 million, a P/E ratio of -0.05 and a beta of 0.49.

Hedge Funds Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC purchased a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent filing with the SEC. Institutional investors and hedge funds own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.